In women with early-stage breast cancer, two clinical trials have shown that both whole- and partial-breast radiation therapy are effective at preventing the cancer from returning after breast-conserving surgery.
In an early-phase trial, dabrafenib (Tafinlar) plus trametinib (Mekinist) shrank tumors in patients with advanced biliary tract cancer and adenocarcinoma of the small intestine whose tumors had a specific mutation in the BRAF gene.
A clinical trial showed that ibrutinib (Imbruvica) plus rituximab (Rituxan) was superior to standard treatment for patients aged 70 and younger with untreated chronic lymphocytic leukemia. Findings from the NCI-sponsored study were announced on December 4 at the American Society of Hematology annual meeting.
In the largest-ever randomized trial testing vitamin D for cancer prevention, the supplement did not lower the risk of developing cancer. The Vitamin D and Omega-3 Trial (VITAL) includes a nationally representative sample of nearly 26,000 participants with no history of invasive cancer.
This page provides information to people who want to participate in clinical trials at NCI’s Developmental Therapeutics Clinic (DTC) in Bethesda, Maryland. The clinic specializes in
developing new cancer treatments by examining the way treatments work in cancer cells within the human body.
NCI's Center for Cancer Research conducts more than 150 cancer and HIV clinical trials at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. Cancer and HIV clinical trials at the NIH Clinical Center are open to patients with cancer or HIV from anywhere in the United States.
NCI-Supported Clinical Trials That Are Recruiting Patients
This phase 1/2 trial is testing an experimental antibody, ganitumab, in combination with dasatinib (Sprycel) for pediatric and adult patients with rhabdomyosarcoma, a cancer of the
skeletal muscles, that has come back or has not responded to treatment. The study will help determine if the combination treatment is safe and if it slows the growth of tumors in people with either embryonal or alveolar rhabdomyosarcoma.
This phase 3 trial tests how well treatment with the combination of gemcitabine (Gemzar) and cisplatin, with or without nab-paclitaxel (Abraxane), works in patients with newly
diagnosed biliary tract cancers that have spread to other parts of the body. Doctors want to see if adding nab-paclitaxel to gemcitabine and cisplatin will affect overall survival for these
This first-in-humans phase 1 trial is studying an experimental biological agent called NEO-201 in patients with solid tumors who have not been helped by prior treatments. Doctors want to determine the best dose and examine the safety of NEO-201 when given intravenously.
